



## Clinical trial results:

### An Open-Label, Single-Dose Study to Assess the Safety of 500- mg Mebendazole Chewable Formulation in Children 2 to 10 Years of Age, Inclusive

#### Summary

EudraCT number	2015-001226-42
Trial protocol	Outside EU/EEA
Global end of trial date	12 March 2010

#### Results information

Result version number	v2 (current)
This version publication date	01 July 2016
First version publication date	05 August 2015
Version creation reason	<ul style="list-style-type: none"><li>• Correction of full data set</li><li>Review of data</li></ul>

#### Trial information

##### Trial identification

Sponsor protocol code	MEBENDAZOLGAI3002
-----------------------	-------------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01173562
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	Johnson & Johnson Pharmaceutical Research & Development
Sponsor organisation address	Turnhoutseweg 30, 2340 Beerse, Belgium,
Public contact	Clinical Registry Group-JB BV, Johnson & Johnson Pharmaceutical Research & Development, ClinicalTrialsEU@its.jnj.com
Scientific contact	Clinical Registry Group-JB BV, Johnson & Johnson Pharmaceutical Research & Development, ClinicalTrialsEU@its.jnj.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 March 2010
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	12 March 2010
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To assess the safety and tolerability of a mebendazole 500-mg chewable tablet formulation in a pediatric population (children 2 to 10 years of age, inclusive).

Protection of trial subjects:

The safety assessments included Adverse events, vital sign measurements (axillary temperature, pulse, respiratory rate, and Blood Pressure [BP]) and Physical examinations (including height and body weight).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 February 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Tanzania, United Republic of: 396
Worldwide total number of subjects	396
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	396
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 396 participants were enrolled and treated with a Single dose of Mebendazole 500 mg.

### Period 1

Period 1 title	Open Label (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

<b>Arm title</b>	Mebendazole 500 mg
------------------	--------------------

Arm description:

Participants received a single dose of Mebendazole 500-mg chewable tablet on Day 1.

Arm type	Experimental
Investigational medicinal product name	MEBENDAZOLE
Investigational medicinal product code	SUB08660MIG
Other name	
Pharmaceutical forms	Chewable tablet
Routes of administration	Oral use

Dosage and administration details:

A single Dose of Mebendazole Chewable tablet 500 mg administered.

<b>Number of subjects in period 1</b>	Mebendazole 500 mg
Started	396
Completed	390
Not completed	6
Noncompliance with study drug	6

## Baseline characteristics

### Reporting groups

Reporting group title | Mebendazole 500 mg

Reporting group description:

Participants received a single dose of Mebendazole 500-mg chewable tablet on Day 1.

Reporting group values	Mebendazole 500 mg	Total	
Number of subjects	396	396	
Title for AgeCategorical Units: subjects			
Children (2-11 years)	396	396	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
From 65 to 84 years	0	0	
85 years and over	0	0	
Title for AgeContinuous Units: years			
arithmetic mean	4.6		
standard deviation	± 1.94	-	
Title for Gender Units: subjects			
Female	190	190	
Male	206	206	

## End points

### End points reporting groups

Reporting group title	Mebendazole 500 mg
Reporting group description:	Participants received a single dose of Mebendazole 500-mg chewable tablet on Day 1.
Subject analysis set title	Safety Analysis Set (SAS)
Subject analysis set type	Safety analysis
Subject analysis set description:	Safety Analysis Set (SAS) includes Participants who received a single dose of mebendazole 500 mg and contributed any safety data after the start of study treatment.

### Primary: Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)

End point title	Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) <sup>[1]</sup>
End point description:	An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
End point type	Primary
End point timeframe:	Up to 3 days after study drug administration
Notes:	[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics were done, no inferential statistical analyses were performed

<b>End point values</b>	Mebendazole 500 mg			
Subject group type	Reporting group			
Number of subjects analysed	396			
Units: participants				
number (not applicable)				
Adverse Events	44			
Serious AEs	0			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants with Abnormal Vital Signs

End point title	Number of Participants with Abnormal Vital Signs
End point description:	Vital signs included assessment of axillary temperature, pulse, respiratory rate, and BP on Day 1 and Day 3
End point type	Secondary
End point timeframe:	Up to 3 Days after study drug administration

<b>End point values</b>	Mebendazole 500 mg			
Subject group type	Reporting group			
Number of subjects analysed	396			
Units: participants				
number (not applicable)	289			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants with Abnormal Physical Examinations at End-of-Study (EOS)

End point title	Number of Participants with Abnormal Physical Examinations at End-of-Study (EOS)			
End point description:	Physical examination included evaluation of body organs (Skin, Eyes, Ears, Nose, Throat, Head, Neck, Thyroid, Heart, Lung, Chest (include Breasts), Abdomen, Genitalia, Anorectal, Lymph nodes, Musculoskeletal, Neurological, Other)			
End point type	Secondary			
End point timeframe:	Up to 3 Days after study drug administration			

<b>End point values</b>	Mebendazole 500 mg			
Subject group type	Reporting group			
Number of subjects analysed	396			
Units: participants				
number (not applicable)	47			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to 3 days after study drug administration

Assessment type Non-systematic

### Dictionary used

Dictionary name MedDRA

Dictionary version 12.1

### Reporting groups

Reporting group title Mebendazole 500 mg

Reporting group description:

Participants received a single dose of Mebendazole 500-mg chewable tablet on Day 1.

<b>Serious adverse events</b>	Mebendazole 500 mg		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 396 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Mebendazole 500 mg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	44 / 396 (11.11%)		
Investigations			
Cardiac Murmur			
subjects affected / exposed	1 / 396 (0.25%)		
occurrences (all)	1		
Respiratory Rate			
subjects affected / exposed	1 / 396 (0.25%)		
occurrences (all)	1		
Respiratory Rate Increased			
subjects affected / exposed	2 / 396 (0.51%)		
occurrences (all)	2		
Nervous system disorders			

Dizziness subjects affected / exposed occurrences (all)	1 / 396 (0.25%) 1		
Headache subjects affected / exposed occurrences (all)	1 / 396 (0.25%) 1		
Blood and lymphatic system disorders Lymphadenopathy subjects affected / exposed occurrences (all)	8 / 396 (2.02%) 8		
General disorders and administration site conditions Pyrexia subjects affected / exposed occurrences (all)	11 / 396 (2.78%) 11		
Gastrointestinal disorders Abdominal Distension subjects affected / exposed occurrences (all)	1 / 396 (0.25%) 1		
Abdominal Pain subjects affected / exposed occurrences (all)	2 / 396 (0.51%) 2		
Aphthous Stomatitis subjects affected / exposed occurrences (all)	1 / 396 (0.25%) 1		
Diarrhoea subjects affected / exposed occurrences (all)	10 / 396 (2.53%) 10		
Nausea subjects affected / exposed occurrences (all)	1 / 396 (0.25%) 1		
Oral Pain subjects affected / exposed occurrences (all)	1 / 396 (0.25%) 1		
Hepatobiliary disorders Jaundice			

subjects affected / exposed occurrences (all)	1 / 396 (0.25%) 1		
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed occurrences (all)	1 / 396 (0.25%) 1		
Dyspnoea			
subjects affected / exposed occurrences (all)	1 / 396 (0.25%) 1		
Epistaxis			
subjects affected / exposed occurrences (all)	1 / 396 (0.25%) 1		
Cough			
subjects affected / exposed occurrences (all)	5 / 396 (1.26%) 5		
Rhonchi			
subjects affected / exposed occurrences (all)	1 / 396 (0.25%) 1		
Skin and subcutaneous tissue disorders			
Rash Papular			
subjects affected / exposed occurrences (all)	3 / 396 (0.76%) 3		
Infections and infestations			
Bronchitis			
subjects affected / exposed occurrences (all)	2 / 396 (0.51%) 2		
Upper Respiratory Tract Infection			
subjects affected / exposed occurrences (all)	1 / 396 (0.25%) 1		
Urinary Tract Infection			
subjects affected / exposed occurrences (all)	1 / 396 (0.25%) 1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 October 2009	The overall reason for the amendment was (1) to change the protocol title to clarify that mebendazole 500 mg is a new formulation of an existing drug (VERMOX®) (2) replacement of oral temperature with axillary temperatur (3) to provide clarification on collection of stool samples (4) to address IRB concern on adverse events (5) removal of reference to blood plasma and urine samples.
21 January 2010	The overall reason for the amendment was to modify wording of exclusion criteria and removal of reference to mebendazole as VERMOX.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported